Enzon Pharmaceuticals Files 8-K for Material Agreement

TL;DR

Enzon Pharma filed an 8-K for a big deal, details to come.

AI Summary

Enzon Pharmaceuticals, Inc. filed an 8-K on October 24, 2025, reporting a material definitive agreement. The filing also includes Regulation FD disclosures and financial statements/exhibits. Specific details of the agreement, including parties involved and financial terms, are not provided in this excerpt.

Why It Matters

This filing indicates a significant business development for Enzon Pharmaceuticals, potentially impacting its operations, partnerships, or financial standing.

Risk Assessment

Risk Level: medium — The filing indicates a material definitive agreement, which could carry significant implications, but the lack of specific details prevents a definitive risk assessment.

Key Players & Entities

• ENZON PHARMACEUTICALS, INC. (company) — Registrant
• October 24, 2025 (date) — Date of Report
• Delaware (jurisdiction) — State of Incorporation
• 22-2372868 (identifier) — IRS Employer Identification No.

FAQ

Key Financial Figures

• $0.01 — f each share of common stock, par value $0.01 per share, of Viskase (the " Viskase Co

Filing Documents

• tm2529311d1_8k.htm (8-K) — 48KB
• tm2529311d1_ex2-1.htm (EX-2.1) — 52KB
• tm2529311d1_ex10-1.htm (EX-10.1) — 26KB
• tm2529311d1_ex99-1.htm (EX-99.1) — 21KB
• tm2529311d1_ex99-1img01.jpg (GRAPHIC) — 2KB
• tm2529311d1_ex99-1img02.jpg (GRAPHIC) — 3KB
• 0001104659-25-102127.txt ( ) — 340KB
• enzn-20251024.xsd (EX-101.SCH) — 3KB
• enzn-20251024_lab.xml (EX-101.LAB) — 33KB
• enzn-20251024_pre.xml (EX-101.PRE) — 22KB
• tm2529311d1_8k_htm.xml (XML) — 3KB

01

Item 1.01 Entry into a Material Definitive Agreement On October 24, 2025, Enzon Pharmaceuticals, Inc., a Delaware corporation (the " Company " or " Enzon "), entered into (i) an amendment (the " Merger Agreement Amendment "), dated as of October 24, 2025, to the Agreement and Plan of Merger (the " Merger Agreement "), dated as of June 20, 2025, by and among Enzon, EPSC Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of the Company (" Merger Sub "), and Viskase Companies, Inc., a Delaware corporation (" Viskase "), and (ii) an amendment (the " Support Agreement Amendment " and, together with the Merger Agreement Amendment, the " Amendments "), dated as of October 24, 2025, to the Support Agreement (the " IEH Support Agreement "), dated as of June 20, 2025, by and among Icahn Enterprises Holdings L.P. (" IEH ") and certain of its affiliates, Enzon and Viskase. The Amendments were entered into in order to reflect recent developments in the operations of Viskase during the past several months and its expected operations in the near term. Pursuant to the terms of the Amendments, the parties agreed, among other things, to: (i) an adjustment to the exchange ratio as calculated under the Merger Agreement for the exchange of each share of common stock, par value $0.01 per share, of Viskase (the " Viskase Common Stock "), issued and outstanding immediately prior to the merger (the " Merger ") of Merger Sub with and into Viskase, with Viskase surviving the Merger as a wholly owned subsidiary of Enzon (other than shares held by holders that properly exercise dissenters rights, shares held in treasury, and shares held by Enzon, Merger Sub or a wholly owned subsidiary of Viskase, Enzon or Merger Sub) into shares of the common stock, par value $0.01 per share, of Enzon (the " Enzon Common Stock "), such that the current Viskase stockholders will own 55% of the combined company following the Merger; (ii) an adjustment to the exchange ratio for the exc

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure On October 24, 2025, the Company and Viskase issued a joint press release announcing entry into the Amendments. A copy of the press release is attached as Exhibit 99.1 hereto and incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the foregoing information, including Exhibit 99.1 shall not be deemed "filed" for the purposes of Section 18 of the Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information, including Exhibit 99.1 be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. Important Information About the Merger and Where to Find It In connection with the proposed transactions between Enzon and Viskase, Enzon intends to file a registration statement on Form S-4 with the SEC that will contain a consent solicitation statement and prospectus (the " Registration Statement "). The Registration Statement will include financial information regarding the combined company. This communication is not a substitute for the Registration Statement or any other documents that Enzon may file with the SEC or that Enzon or Viskase may send to their respective stockholders in connection with the transactions contemplated by the Merger Agreement, as amended. BEFORE MAKING ANY VOTING DECISION, ENZON AND VISKASE URGE INVESTORS AND STOCKHOLDERS TO READ THESE MATERIALS CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT ENZON, THE COMBINED COMPANY, THE MERGER AGREEMENT, AS AMENDED, AND THE TRANSACTIONS CONTEMPLATED THEREBY, INCLUDING THE MERGER, AND RELATED MATTERS. You may obtain free copies of the Registration by t

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit Description 2.1 First Amendment to Agreement and Plan of Merger, dated as of October 24, 2025, by and between Enzon Pharmaceuticals, Inc., EPSC Acquisition Corp., and Viskase Companies, Inc. 10.1 First Amendment to Support Agreement, dated as of October 24, 2025, by and between Icahn Enterprises Holdings L.P. and certain of its affiliates, Enzon Pharmaceuticals, Inc. and Viskase Companies, Inc. 99.1 Press Release, dated October 24, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ENZON PHARMACEUTICALS, INC. (Registrant) Date: October 24, 2025 By: /s/ Richard L. Feinstein Name: Richard L. Feinstein Title: Chief Executive Officer, Chief Financial Officer and Secretary

View Full Filing

View this 8-K filing on SEC EDGAR